» Articles » PMID: 7133135

A Point Mutation is Responsible for the Acquisition of Transforming Properties by the T24 Human Bladder Carcinoma Oncogene

Overview
Journal Nature
Specialty Science
Date 1982 Nov 11
PMID 7133135
Citations 339
Authors
Affiliations
Soon will be listed here.
Abstract

The genetic change that leads to the activation of the oncogene in T24 human bladder carcinoma cells is shown to be a single point mutation of guanosine into thymidine. This substitution results in the incorporation of valine instead of glycine as the twelfth amino acid residue of the T24 oncogene-encoded p21 protein. Thus, a single amino acid substitution appears to be sufficient to confer transforming properties on the gene product of the T24 human bladder carcinoma oncogene.

Citing Articles

Unravelling cancer subtype-specific driver genes in single-cell transcriptomics data with CSDGI.

Huang M, Ma J, An G, Ye X PLoS Comput Biol. 2023; 19(12):e1011450.

PMID: 38096269 PMC: 10754467. DOI: 10.1371/journal.pcbi.1011450.


Oncogenic KRAS, Mucin 4, and Activin A-Mediated Fibroblast Activation Cooperate for PanIN Initiation.

Hu C, Huang C, Hsu M, Chien H, Wu P, Chen Y Adv Sci (Weinh). 2023; 10(36):e2301240.

PMID: 37964407 PMC: 10754145. DOI: 10.1002/advs.202301240.


The Epigenetic Reader Methyl-CpG-Binding Protein 2 (MeCP2) Is an Emerging Oncogene in Cancer Biology.

Nejati-Koshki K, Roberts C, Babaei G, Rastegar M Cancers (Basel). 2023; 15(10).

PMID: 37345019 PMC: 10216337. DOI: 10.3390/cancers15102683.


Transforming Diagnosis and Therapeutics Using Cancer Genomics.

Mehmood S, Aslam S, Dilshad E, Ismail H, Khan A Cancer Treat Res. 2023; 185:15-47.

PMID: 37306902 DOI: 10.1007/978-3-031-27156-4_2.


Variant biomarker discovery using mass spectrometry-based proteogenomics.

Reilly L, Seddighi S, Singleton A, Cookson M, Ward M, Qi Y Front Aging. 2023; 4:1191993.

PMID: 37168844 PMC: 10165118. DOI: 10.3389/fragi.2023.1191993.